<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jcm-09-02084-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">jcm-09-02084-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Interim coronavirus disease (COVID-19) therapeutic guidelines in different countries dependent on clinical stage.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Status</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Belgium</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Italy
     <break/>(Lombardia Protocol)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">France</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Switzerland</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Romania</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate—no risk group</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptomatic care (paracetamol) 
     <break/>No antiviral treatment
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No antiviral treatment</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No antiviral treatment</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No antiviral treatment</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No antiviral treatment</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ambulatory symptomatic care—paracetamol—500 mg/3x/day
     <break/>Hospital treatment—HCQ—400 mg/2x/day—only on day 1 and 200 mg/2x/day—5–6 days
     <break/>Second choice—LPV/r—400/100 mg/2x/day—5–7 days
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate—risk group</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCQ 400 mg at suspicion/diagnosis; 400 mg—12 h later and 200 mg—until day 5—in the absence of HCQ consider CQ base (600 mg/diagnosis; 300 mg—12 h later and 300 mg up to 5 days) or CQ phosphate (1000 mg/diagnosis; 500 mg—12 h later and 300 mg up to 5 days)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPV/r (400/100 mg/BD) + CQ (500 mg/BD) or HCQ (200 mg/BD)—5–7 days </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPV/r (400/100 mg/BD) (under consideration)
     <break/>Treatment period—depending on the viral excretion 
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CQ—5 days (under consideration day 1: 600–300 mg; days 2–5: 300 mg)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not mentioned</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCQ (400 mg/2x/day—only on day 1 and 200 mg/2x/day—4 days) + LPV/r (400/100 mg/2x/day)—10–14 days</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe disease</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCQ—400 mg at suspicion/diagnosis; 400 mg—12 h later and 200 mg—until day 5—in the absence of HCQ consider CQ base (600 mg/diagnosis; 300 mg—12 h later and 300 mg up to 5 days) or CQ phosphate (1000 mg/diagnosis; 500 mg—12 h later and 300 mg up to 5 days)
     <break/>Second option: LPV/r 400/100 mg (=2 tablets of 200/50 mg) BD for 14 days
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (200 mg/day—day 1 followed by 100 mg/day days 2–10) + CQ (500 mg/BD) or HCQ (200 mg/BD)—5–20 days (in the absence of RDV, it can be maintained LPV/r+ CQ)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (200 mg/day—day 1 followed by 100 mg/day days 2–10)
     <break/>Treatment period—depending on the viral excretion 
     <break/>No second option
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CQ—5 days (day 1: 600–300 mg; days 2–5: 300 mg)
     <break/>LPV/r (400/100 mg/BD) as second choice—10–14 days
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPV/r (400/100 mg/BD) (atazanavir/ritonavir as second option)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCQ (400 mg/2x/days—only on day 1 and 200 mg/2x/day—4–20 days) + RDV (200 mg/day—only on day 1, followed by 100 mg/day for other 9 days)
     <break/>Second choice for RDV is LPV/r, but only until RDV is obtained.
     <break/>± Tocilizumab (only to patient that present “cytokine storm” and organ dysfunctions)—8 mg/kg body weight (maximum 800 mg)—lent perfusion—1–3 doses at 8 h interval
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Critical disease</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (compassionate use)
     <list list-type="bullet">
      <list-item>
       <p>200 mg loading dose (IV, within 30 min)</p>
      </list-item>
      <list-item>
       <p>100 mg OD for 2 to 10 days</p>
      </list-item>
     </list> In the absence of RDV—(HCQ, crushed in nasogastric tube, at the same dosage)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (200 mg/day—day 1 followed by 100 mg/day days 2–10) + CQ (500 mg/BD) or HCQ (200 mg/BD)—5–20 days (in the absence of RDV, it can be maintained LPV/r+ CQ)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (200 mg/day—day 1 followed by 100 mg/day days 2–10)
     <break/>Treatment period—depending on the viral excretion 
     <break/>LPV/r—as second option (case by case)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV (for 10 days—200 mg/day—day 1 followed by 100 mg/day days 2–10) + CQ (for 5 days—day 1: 600–300 mg; days 2–5: 300 mg)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDV—10 days (200 mg/day—day 1 followed by 100 mg/day days 2–10)
     <break/>LPV/r (400/100 mg/BD) (+HCQ if &lt;65 years/no comorbidity) as second choice (if RDV is unavailable).
     <break/>Tocilizumab (in the case of MOF and inotropic support)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>HCQ—hydroxychloroquine; CQ—chloroquine; LPV/r—lopinavir/ritonavir; RDV—remdesivir; MOF—multiorgan failure; BD—twice a day; IV–intravenous; OD–once a day.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
